Catalio Capital Management LP Takes Position in Heartflow, Inc. $HTFL

Catalio Capital Management LP purchased a new stake in Heartflow, Inc. (NASDAQ:HTFL) in the fourth quarter, Holdings Channel reports. The institutional investor purchased 113,857 shares of the company’s stock, valued at approximately $3,319,000.

A number of other large investors also recently modified their holdings of the company. Bamco Inc. NY lifted its stake in shares of Heartflow by 86.2% in the 4th quarter. Bamco Inc. NY now owns 2,303,877 shares of the company’s stock valued at $67,158,000 after acquiring an additional 1,066,371 shares during the last quarter. Boothbay Fund Management LLC bought a new position in shares of Heartflow in the 4th quarter valued at $330,000. Freestone Grove Partners LP lifted its stake in shares of Heartflow by 400.0% in the 4th quarter. Freestone Grove Partners LP now owns 150,000 shares of the company’s stock valued at $4,372,000 after acquiring an additional 120,000 shares during the last quarter. Sandia Investment Management LP lifted its stake in shares of Heartflow by 112.2% in the 4th quarter. Sandia Investment Management LP now owns 15,917 shares of the company’s stock valued at $464,000 after acquiring an additional 8,417 shares during the last quarter. Finally, Rock Springs Capital Management LP lifted its stake in shares of Heartflow by 11.1% in the 4th quarter. Rock Springs Capital Management LP now owns 277,700 shares of the company’s stock valued at $8,095,000 after acquiring an additional 27,700 shares during the last quarter.

Heartflow Trading Up 2.5%

Shares of Heartflow stock opened at $32.84 on Thursday. The business has a 50-day moving average price of $29.74 and a two-hundred day moving average price of $28.34. Heartflow, Inc. has a 1-year low of $20.13 and a 1-year high of $41.22. The company has a market cap of $2.83 billion and a P/E ratio of -10.56.

Heartflow (NASDAQ:HTFL) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.08. The business had revenue of $52.59 million for the quarter. Heartflow’s quarterly revenue was up 41.3% compared to the same quarter last year. Equities research analysts forecast that Heartflow, Inc. will post -0.82 EPS for the current fiscal year.

Insiders Place Their Bets

In other Heartflow news, major shareholder Bain Capital Life Sciences Inv sold 948,757 shares of the stock in a transaction dated Thursday, April 30th. The stock was sold at an average price of $29.23, for a total transaction of $27,732,167.11. Following the completion of the sale, the insider directly owned 8,448,158 shares in the company, valued at approximately $246,939,658.34. This trade represents a 10.10% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Campbell Rogers sold 9,219 shares of the stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $28.34, for a total value of $261,266.46. Following the sale, the insider owned 78,731 shares of the company’s stock, valued at approximately $2,231,236.54. The trade was a 10.48% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 2,141,438 shares of company stock worth $62,651,098. Company insiders own 7.70% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on HTFL. JPMorgan Chase & Co. dropped their price target on Heartflow from $40.00 to $35.00 and set an “overweight” rating for the company in a research note on Thursday, March 19th. Piper Sandler restated an “overweight” rating on shares of Heartflow in a report on Thursday, June 11th. Wells Fargo & Company increased their price objective on Heartflow from $35.00 to $37.00 and gave the company an “overweight” rating in a report on Friday, May 15th. William Blair started coverage on Heartflow in a report on Monday, May 4th. They issued an “outperform” rating for the company. Finally, Canaccord Genuity Group decreased their price objective on Heartflow from $43.00 to $37.00 and set a “buy” rating for the company in a report on Friday, May 15th. Six investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $37.00.

Heartflow Company Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.